OncoTherapy Science, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 35

OncoTherapy Science, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “OncoTherapy Science, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- OncoTherapy Science, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of OncoTherapy Science, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of OncoTherapy Science, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the OncoTherapy Science, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate OncoTherapy Science, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of OncoTherapy Science, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the OncoTherapy Science, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with OncoTherapy Science, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of OncoTherapy Science, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
OncoTherapy Science, Inc. Snapshot
OncoTherapy Science, Inc. Overview
Key Information
Key Facts
OncoTherapy Science, Inc. – Research and Development Overview
Key Therapeutic Areas
OncoTherapy Science, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
OncoTherapy Science, Inc. – Pipeline Products Glance
OncoTherapy Science, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
OncoTherapy Science, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
OncoTherapy Science, Inc. – Drug Profiles
OTS102 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
A0041
Product Description
Mechanism of Action
R&D Progress
B5860N
Product Description
Mechanism of Action
R&D Progress
C2093
Product Description
Mechanism of Action
R&D Progress
C6776
Product Description
Mechanism of Action
R&D Progress
D0587
Product Description
Mechanism of Action
R&D Progress
OncoTherapy Science, Inc. – Pipeline Analysis
OncoTherapy Science, Inc. – Pipeline Products by Therapeutic Class
OncoTherapy Science, Inc. Pipeline Products By Target
OncoTherapy Science, Inc. – Pipeline Products by Route of Administration
OncoTherapy Science, Inc. – Pipeline Products by Molecule Type
OncoTherapy Science, Inc. - Dormant Projects
OncoTherapy Science, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Deals Landscape
OncoTherapy Science, Inc., Deals Volume Summary, 2004 to YTD 2010
OncoTherapy Science, Inc., Deals Summary By Region, 2004 to YTD 2010
OncoTherapy Science, Inc., Deals Summary, 2004 to YTD 2010
OncoTherapy Science, Inc. Detailed Deal Summary
OncoTherapy Science Enters Into Research Agreement With Carna Biosciences And CrystalGenomics
Yakult Honsha Enters Into Co-Development Agreement With OncoTherapy Science
Licensing Agreements
Shionogi Enters Into A License Agreement With OncoTherapy Science
OncoTherapy Science Enters Into Licensing Agreement With Institute for Antibodies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Aerospace and Defense Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Homeland Security and Emergency Management Market, 2013–2018
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles